A depot-forming glucagon-like peptide-1 fusion protein reduces blood glucose for five days with a single injection

Peptide drugs are an exciting class of pharmaceuticals for the treatment of a variety of diseases; however, their short half-life dictates multiple and frequent injections causing undesirable side effects. Herein, we describe a novel peptide delivery system that seeks to combine the attractive featu...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of controlled release 2013-11, Vol.172 (1), p.144-151
Hauptverfasser:	Amiram, M., Luginbuhl, K.M., Li, X., Feinglos, M.N., Chilkoti, A.
Format:	Artikel
Sprache:	eng
Schlagworte:	adverse effects Amino Acid Sequence Animals blood glucose Blood Glucose - metabolism body temperature Delayed-Action Preparations - chemistry Drug delivery drugs Elastin - administration & dosage Elastin - chemistry Elastin - pharmacology Elastin-like polypeptide Glucagon-Like Peptide 1 - administration & dosage Glucagon-Like Peptide 1 - chemistry Glucagon-Like Peptide 1 - pharmacology Glucagon-like peptide-1 half life Hypoglycemic Agents - administration & dosage Hypoglycemic Agents - chemistry Hypoglycemic Agents - pharmacology Injections Male Mice Mice, Inbred C57BL Molecular Sequence Data noninsulin-dependent diabetes mellitus Peptide Phase Transition proteolysis Recombinant Fusion Proteins - administration & dosage Recombinant Fusion Proteins - chemistry Recombinant Fusion Proteins - pharmacology Subcutaneous depot
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!